Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9966382 | 1.00 | MME (0.46) | MMEMAPTTDP1CYP19A1MAOB | |
| SCHEMBL9979898 | 1.00 | MME (0.46) | MMEMAPTTDP1CYP19A1MAOB | |
| SCHEMBL14978999 | 0.84 | MME (0.46) | MMEMAPTTDP1CYP19A1MEN1 | |
| SCHEMBL15474173 | 0.84 | MME (0.46) | MMEMAPTTDP1CYP19A1MEN1 | |
| SCHEMBL15474172 | 0.84 | MME (0.46) | MMEMAPTTDP1CYP19A1MEN1 | |
| SCHEMBL23119120 | 0.81 | MME (0.47) | MMECYP19A1 | |
| SCHEMBL21650176 | 0.81 | MME (0.43) | MME | |
| SCHEMBL23119130 | 0.81 | MME (0.43) | MME | |
| SCHEMBL9963907 | 0.81 | MME (0.44) | MMECYP19A1GRM5 | |
| SCHEMBL9963906 | 0.81 | MME (0.44) | MMECYP19A1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157383-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157383-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885MAPT 556/4885TDP1 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.